Abstract
Biologic therapy is a new treatment option for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Currently, the only biologic with Food and Drug Administration–approval status for CRSwNP is dupilumab. Several other biologics are likely to be approved for CRSwNP, including mepolizumab and omalizumab, based on their promising phase 3 trial results. The role of biologics in the treatment paradigm requires consideration of multiple factors that have yet to be clearly established. This includes identifying patients most appropriate for biologic therapy while considering long-term safety and cost-effectiveness in the context of patient preferences and goals.
Original language | English (US) |
---|---|
Pages (from-to) | 44-47 |
Number of pages | 4 |
Journal | Ear, Nose and Throat Journal |
Volume | 100 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2021 |
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported my National Institute of Health grant T32AI083216; Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine; and by the Ernest Bazley Foundation.
Keywords
- benralizumab
- biologics
- chronic rhinosinusitis with nasal polyps (CRSwNP)
- dupilumab
- mepolizumab
- nasal polyps
- omalizumab
ASJC Scopus subject areas
- Otorhinolaryngology